Memantine

Memantine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Memantine is an Uncompetitive N-methyl-D-aspartate Receptor Antagonist that is FDA approved for the {{{indicationType}}} of moderate to severe dementia of the Alzheimer's type. Common adverse reactions include Hypertension, Hypotension, Syncope, Diarrhea, Vomiting, Backache, Confusion, Dizziness, Headache, Cough, Pain.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Dementia

• Dosing information

• Recommended dosage: 28 mg PO qd. (In a controlled clinical trial)
• Recommended starting dosage: 7 mg PO qd.
• Recommended target dosage: 28 mg PO qd. The dose should be increased in 7 mg increments to 28 mg once daily. The minimum recommended interval between dose increases is one week, and only if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.

NAMENDA XR can be taken with or without food. NAMENDA XR capsules can be taken intact or may be opened, sprinkled on applesauce, and thereby swallowed. The entire contents of each NAMENDA XR capsule should be consumed; the dose should not be divided. Except when opened and sprinkled on applesauce, as described above, NAMENDA XR should be swallowed whole. NAMENDA XR capsules should not be divided, chewed, or crushed. Switching from NAMENDA Tablets to NAMENDA XR Capsules: Patients treated with NAMENDA tablets may be switched to NAMENDA XR capsules as follows: It is recommended that a patient who is on a regimen of 10 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 28 mg once daily capsules the day following the last dose of a 10 mg NAMENDA tablet. There is no study addressing the comparative efficacy of these 2 regimens. In a patient with severe renal impairment, it is recommended that a patient who is on a regimen of 5 mg twice daily of NAMENDA tablets be switched to NAMENDA XR 14 mg once daily capsules the day following the last dose of a 5 mg NAMENDA tablet.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Memantine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Memantine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Memantine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Memantine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Memantine in pediatric patients.

Contraindications

There is limited information regarding Memantine Contraindications in the drug label.

Warnings

There is limited information regarding Memantine Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Memantine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Memantine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Memantine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Memantine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Memantine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Memantine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Memantine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Memantine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Memantine in geriatric settings.

Gender

There is no FDA guidance on the use of Memantine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Memantine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Memantine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Memantine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Memantine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Memantine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Memantine Administration in the drug label.

Monitoring

There is limited information regarding Memantine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Memantine and IV administrations.

Overdosage

There is limited information regarding Memantine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Memantine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Memantine Mechanism of Action in the drug label.

Structure

There is limited information regarding Memantine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Memantine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Memantine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Memantine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Memantine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Memantine How Supplied in the drug label.

Storage

There is limited information regarding Memantine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Memantine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Memantine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Memantine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Memantine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Memantine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Memantine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.